Nuvalent, Inc. (NUVL) FY2025 10-K Annual Report
Nuvalent, Inc. (NUVL) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Nuvalent, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model focused on biopharmaceutical development and innovation
- • No new products, services, or segments introduced or emphasized this year
- • Maintained executive employment agreements with key leadership, including CEO James R. Porter and five other executives
- • Proxy statement information (executive compensation, stock ownership, related transactions) incorporated by reference, not detailed herein
- • Employment agreements amended in 2024 for James R. Porter and other executives, reflecting updated contractual arrangements
Management Discussion & Analysis
- • Net loss $425.4M in 2025 vs $260.8M in 2024; operating cash outflow $275.2M vs $185.1M
- • Operating cash flow decline due to higher clinical, manufacturing, personnel expenses; stock-based comp $86.5M vs $60.6M
- • Cash, cash equivalents, and marketable securities $1.4B at 2025 year-end, expected to fund operations through 2029
- • Investing cash outflow $124.1M in 2025, driven by $1.1B marketable securities purchases offset by $932.8M maturities
- • Financing cash inflow $515.3M in 2025 from public offering ($472.5M net proceeds) and option exercises ($42M)
- • No revenue or net sales reported; revenue share liabilities measured at $73.2M vs $17.9M due to fair value changes
- • Management highlights significant R&D and commercialization spending ahead, potential additional capital raises anticipated due to uncertain future funding needs
Risk Factors
- • FDA acceptance of NDA for zidesamtinib with PDUFA date September 18, 2026, critical regulatory milestone risk
- • Exposure to macroeconomic risks including inflation, interest rate fluctuations, and geopolitical tensions impacting funding access
- • Dependence on contract manufacturing organizations (CMOs) for scale-up and commercial batch production of drug substances
- • Market competition from ALECENSA (alectinib) in Phase 3 ALKAZAR trial for ALK-positive NSCLC targeting 450 patients
- • Net losses expanding to $425.4 million in 2025 with $1.4 billion cash runway only through 2029, capital raise dependency risk
Nuvalent, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$425M
▼ -63.1% YoY
ROE
-34.1%
▼ -970bp YoY
Total Assets
$1.4B
▲ +23.7% YoY
EPS (Diluted)
$-5.85
▼ -48.9% YoY
Operating Cash Flow
-$275M
▼ -48.7% YoY
Source: XBRL data from Nuvalent, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Nuvalent, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.